Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry
Alessandro Pastore(Ludwig-Maximilians-Universität München), Vindi Jurinović(Ludwig-Maximilians-Universität München), Robert Kridel(BC Cancer Agency), Eva Hoster(Ludwig-Maximilians-Universität München), Annette M. Staiger(Robert Bosch Hospital), Monika Szczepanowski(University Hospital Schleswig-Holstein), Christiane Pott(University Hospital Schleswig-Holstein), Nadja Kopp(Dana-Farber Cancer Institute), Mark A. Murakami(Dana-Farber Cancer Institute), Heike Horn(Robert Bosch Hospital), Ellen Leich(University of Würzburg), Alden A. Moccia(BC Cancer Agency), Anja Mottok(BC Cancer Agency), Ashwini Sunkavalli(Dana-Farber Cancer Institute), Paul Van Hummelen(Dana-Farber Cancer Institute), Matthew D. Ducar(Dana-Farber Cancer Institute), Daisuke Ennishi(BC Cancer Agency), Hennady P. Shulha(BC Cancer Agency), Christoffer Hother(BC Cancer Agency), Joseph M. Connors(BC Cancer Agency), Laurie H. Sehn(BC Cancer Agency), Martin Dreyling(Ludwig-Maximilians-Universität München), Donna Neuberg(Dana-Farber Cancer Institute), Peter Mӧller(Universität Ulm), Alfred C. Feller(University Hospital Schleswig-Holstein), Martin L. Hansmann(Goethe University Frankfurt), Harald Stein(Pathodiagnostik Berlin), Andreas Rosenwald(University of Würzburg), German Ott(Robert Bosch Hospital), Wolfgang Hiddemann(University Hospital Schleswig-Holstein), Michael Unterhalt(Ludwig-Maximilians-Universität München), Wolfgang Hiddemann(German Cancer Research Center), Randy D. Gascoyne(BC Cancer Agency), David M. Weinstock(Dana-Farber Cancer Institute), Oliver Weigert(German Cancer Research Center)
Cited by 611